Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies.

Since its founding in 1992, Alexion has given hope to people who had none and shined a light on those who felt isolated and alone. But we know that fighting rare diseases takes so much more than hope. It requires persistence, dedication, and a relentless pursuit of the highest levels of medical innovation. At Alexion, our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people’s lives are at stake.

Alexion has 2,500 passionate and dedicated employees serving patients in 50 countries around the world.

OUR BREAKTHROUGH THERAPIES
Through the transformative power of our science, Alexion has delivered life-changing therapies to patients suffering from rare diseases. We have pioneered the complex field of complement biology and delivered solutions to challenges that once seemed impossible for patients with devastating complement-mediated and metabolic disorders.

Alexion developed Soliris® (eculizumab), the world’s first approved terminal complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).

Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders—Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).
http://www.alxn.com/
475-230-ALXN (2596)
100 College St
New Haven, CT 06510
http://www.sci.bio/job-search/

Send Message to listing owner

Alexion Pharmaceuticals, Inc.